NEUTRA CORPORATION - NTRR STOCK NEWS

Neutra Corporation announces a two-year management plan to meet the increasing demand for its health and wellness solutions. The plan focuses on expanding the service business, pursuing consulting services, and strengthening the company's position in the specialty healthcare and wellness space. Neutra aims to grow its cannabis-infused products lines, increase direct-to-consumer revenues, and lead the digital transformation of the DTC cannabis product sector. The company also plans to monetize its expertise in the Clinical Trial Market and build a complete solutions ecosystem.

Neutra Corporation (OTC PINK:NTRR) announced a letter of intent to acquire Mercury Clinical Research, enhancing its position in the health and wellness sector. Neutra has resolved its past debt and is working towards successful negotiations for the acquisition. Mercury has shown significant growth, reporting 2022 gross revenues between $3-7 million and positive EBITDA. The acquisition aims to integrate Mercury's capabilities, which are crucial for clinical trials, into Neutra's operations. However, a definitive agreement has yet to be reached, emphasizing uncertainties in finalizing the transaction.

Neutra Corporation (OTC PINK:NTRR) announced a binding letter of intent to acquire Mercury Clinical Research, a site management organization specializing in clinical trials for major pharmaceutical firms. The acquisition aims to bolster Neutra's presence in health, wellness, and life sciences, with a closing anticipated in Q3 2023. The transaction will be funded through a mix of cash and equity, enhancing financial flexibility. Mercury has shown significant growth, achieving 2022 revenues between $3-$6 million with positive EBITDA. This strategic move is expected to create new revenue channels and strengthen Neutra's brand.

Neutra Corporation (OTC PINK:NTRR) announced a positive consumer reception for its new premium vape kit, featuring cartridges for Delta-8, THC-O, and HHC. The CEO reported strong interest from retailers and consumers, highlighting the product’s quality and affordability compared to competitors. Available at over 150 retailers across 17 states and through its redesigned e-commerce site, Deity Wellness aims to enhance its online presence by hiring a social media manager and a web developer to improve SEO and traffic. Early feedback suggests this kit could become a top seller.

Neutra Corp. (OTC PINK:NTRR) is optimistic about the latter half of 2022 despite economic challenges. The company has completed its new manufacturing facility, boasts a variety of revenue-generating CBD products, and has minimal debt. CEO Sydney Jim confirms there are no plans for a reverse stock split, stating the company is in a strong position with no debt holder conversions since 2015. Neutra's growth strategy includes launching new products and enhancing its sales campaigns, with the hemp-derived cannabinoid market projected to reach $8 billion in 2022.

Neutra Corp. (OTC PINK:NTRR) has successfully launched an enhanced ecommerce platform for its subsidiary, Deity Wellness, aimed at boosting online visibility and user experience. The project included a redesign of packaging for Deity’s Delta-8 gummies and vape cartridges to better appeal to consumers. Additionally, Deity is set to introduce a new product anticipated to launch by the end of April 2022. CEO Sydney Jim emphasized the company’s commitment to innovation in a competitive cannabinoid market.

Neutra Corp. (OTC PINK:NTRR) is finalizing upgrades to its ecommerce platforms for subsidiaries VIVIS and Deity Wellness, set to launch within weeks. These enhancements aim to support a new hemp-based product targeting the growing cannabinoid market. CEO Sydney Jim emphasizes the importance of a strong online presence for future success, particularly in today's economy. The revamped sites will improve search visibility and communicate the brands' value propositions, anticipating increased sales and revenue from the shift towards online shopping.

Neutra Corp. (OTC PINK:NTRR) has launched a dynamic sales and marketing initiative at the start of 2022, including a new product line by its subsidiary VIVIS, featuring CBDa and CBGa gummies. These compounds have shown potential in preventing COVID-19's penetration into human cells, according to recent studies. The company aims for continued revenue growth, emphasizing there are no plans for a reverse stock split despite rumors. Enhanced advertising efforts and redesigned e-commerce sites for VIVIS and Deity Wellness aim to attract consumer interest and boost sales further.